Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer

Experimental Cell Research

Volumn 346, Issue 1, 2016, Pages 65-73

  Doddapaneni, Ravi ^a   Patel, Ketan ^a   Chowdhury, Nusrat ^a   Singh, Mandip ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

Chemosensitization; Docetaxel; Noscapine; Triple negative breast cancer; Tumor stroma

Indexed keywords

ANTIFIBROTIC AGENT; COUMARIN 6; COUMARIN DERIVATIVE; DOCETAXEL; LIPOSOME; MACROGOL; MITOGEN ACTIVATED PROTEIN KINASE P38; NANOCARRIER; NOSCAPINE; PROTEIN BCL 2; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; SURVIVIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; NANOPARTICLE; TAXOID; THIAZOLE DERIVATIVE; TUBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL KILLING; CELL MIGRATION; CHEMOSENSITIZATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; IN VIVO STUDY; LIPOSOMAL DELIVERY; LOW DRUG DOSE; MDA MB 231 CELL LINE; MOUSE; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; ANIMAL; CELL MIGRATION ASSAY; CELL MOTION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; METABOLISM; MICROTUBULE; PATHOLOGY; PHOSPHORYLATION; POLYMERIZATION; STAINING; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MIGRATION ASSAYS; CELL MOVEMENT; COUMARINS; DRUG CARRIERS; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPOSOMES; MICE; MICROTUBULES; NANOPARTICLES; NOSCAPINE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; POLYMERIZATION; STAINING AND LABELING; TAXOIDS; THIAZOLES; TRIPLE NEGATIVE BREAST NEOPLASMS; TUBULIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84976504728     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2016.05.006     Document Type: Article

References (45)

1. [1] Foulkes, W.D., Smith, I.E., Reis-Filho, J.S., Triple-negative breast cancer. N. Engl. J. Med. 363 (2010), 1938–1948.
2. [2] Hurvitz, S., Mead, M., Triple-negative breast cancer: advancements in characterization and treatment approach. Curr. Opin. Obstet. Gynecol. 28 (2016), 59–69.
3. [3] Isakoff, S.J., Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 16 (2010), 53–61.
4. [4] Patel, K., Patil, A., Mehta, M., Gota, V., Vavia, P., Medium chain triglyceride (MCT) rich, paclitaxel loaded self nanoemulsifying preconcentrate (PSNP): a safe and efficacious alternative to Taxol. J. Biomed. Nanotechnol. 9 (2013), 1996–2006.
5. [5] O'Reilly, E.A., Gubbins, L., Sharma, S., Tully, R., Guang, M.H., Weiner-Gorzel, K., McCaffrey, J., Harrison, M., Furlong, F., Kell, M., McCann, A., The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin. 3 (2015), 257–275.
6. [6] Rida, P.C., LiVecche, D., Ogden, A., Zhou, J., Aneja, R., The noscapine chronicle: a pharmaco-historic biography of the opiate alkaloid family and its clinical applications. Med. Res. Rev. 35 (2015), 1072–1096.
7. [7] Mahmoudian, M., Rahimi-Moghaddam, P., The anti-cancer activity of noscapine: a review. Recent Pat. Anticancer Drug. Discov. 4 (2009), 92–97.
8. [8] Aneja, R., Dhiman, N., Idnani, J., Awasthi, A., Arora, S.K., Chandra, R., Joshi, H.C., Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemother. Pharmacol. 60 (2007), 831–839.
9. [9] Chougule, M., Patel, A.R., Sachdeva, P., Jackson, T., Singh, M., Anticancer activity of noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer. Lung Cancer 71 (2011), 271–282.
10. [10] Jackson, T., Chougule, M.B., Ichite, N., Patlolla, R.R., Singh, M., Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother. Pharmacol. 63 (2008), 117–126.
11. [11] Qi, Q., Liu, X., Li, S., Joshi, H.C., Ye, K., Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth. Acta Pharmacol. Sin. 34 (2013), 930–938.
12. [12] Ye, K., Ke, Y., Keshava, N., Shanks, J., Kapp, J.A., Tekmal, R.R., Petros, J., Joshi, H.C., Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc. Natl. Acad. Sci. USA 95 (1998), 1601–1606.
13. [13] Newcomb, E.W., Lukyanov, Y., Schnee, T., Ali, M.A., Lan, L., Zagzag, D., Noscapine inhibits hypoxia-mediated HIF-1alpha expression andangiogenesis in vitro: a novel function for an old drug. Int. J. Oncol. 28 (2006), 1121–1130.
14. [14] Aneja, R., Ghaleb, A.M., Zhou, J., Yang, V.W., Joshi, H.C., p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res. 67 (2007), 3862–3870.
15. [15] Newcomb, E.W., Lukyanov, Y., Alonso-Basanta, M., Esencay, M., Smirnova, I., Schnee, T., Shao, Y., Devitt, M.L., Zagzag, D., McBride, W., Formenti, S.C., Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors. Int. J. Radiat. Oncol. Biol. Phys. 71 (2008), 1477–1484.
16. [16] Zhou, J., Gupta, K., Yao, J., Ye, K., Panda, D., Giannakakou, P., Joshi, H.C., Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. J. Biol. Chem. 277 (2002), 39777–39785.
17. [17] Aneja, R., Zhou, J., Vangapandu, S.N., Zhou, B., Chandra, R., Joshi, H.C., Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011. Blood 107 (2006), 2486–2492.
18. [18] Chougule, M.B., Patel, A.R., Jackson, T., Singh, M., Antitumor activity of noscapine in combination with doxorubicin in triple negative breast cancer. PLoS One, 6, 2011, e17733.
19. [19] Chougule, M.B., Patel, A., Sachdeva, P., Jackson, T., Singh, M., Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer. PLoS One, 6, 2011, e27394.
20. [20] Sung, B., Ahn, K.S., Aggarwal, B.B., Noscapine, a benzylisoquinoline alkaloid, sensitizes leukemic cells to chemotherapeutic agents and cytokines by modulating the NF-kappaB signaling pathway. Cancer Res. 70 (2010), 3259–3268.
21. [21] Liu, J., Liao, S., Diop-Frimpong, B., Chen, W., Goel, S., Naxerova, K., Ancukiewicz, M., Boucher, Y., Jain, R.K., Xu, L., TGF-beta blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc. Natl. Acad. Sci. USA 109 (2012), 16618–16623.
22. [22] Patel, K., Doddapaneni, R., Sekar, V., Chowdhury, N., Singh, M., Combination approach of YSA peptide anchored docetaxel stealth liposomes with oral antifibrotic agent for the treatment of lung cancer. Mol. Pharm., 2016.
23. [23] Karousou, E., D'Angelo, M.L., Kouvidi, K., Vigetti, D., Viola, M., Nikitovic, D., De Luca, G., Passi, A., Collagen VI and hyaluronan: the common role in breast cancer. Biomed. Res. Int., 2014, 2014, 606458.
24. [24] Godugu, C., Patel, A.R., Doddapaneni, R., Marepally, S., Jackson, T., Singh, M., Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. J. Control Release 172 (2013), 86–95.
25. [25] Kach, J., Sandbo, N., La, J., Denner, D., Reed, E.B., Akimova, O., Koltsova, S., Orlov, S.N., Dulin, N.O., Antifibrotic effects of noscapine through activation of prostaglandin E2 receptors and protein kinase A. J. Biol. Chem. 289 (2014), 7505–7513.
26. [26] Fulzele, S.V., Chatterjee, A., Shaik, M.S., Jackson, T., Singh, M., Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model. Pharm. Res. 23 (2006), 2094–2106.
27. [27] Doddapaneni, R., Patel, K., Owaid, I.H., Singh, M., Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer. Drug Deliv., 2015, 1–10.
28. [28] Patel, K., Chowdhury, N., Doddapaneni, R., Boakye, C.H., Godugu, C., Singh, M., Piperlongumine for enhancing oral bioavailability and cytotoxicity of docetaxel in triple-negative breast cancer. J. Pharm. Sci., 2015.
29. [29] Parker, A.L., Kavallaris, M., McCarroll, J.A., Microtubules and their role in cellular stress in cancer. Front. Oncol., 4, 2014, 153.
30. [30] Hudis, C.A., Gianni, L., Triple-negative breast cancer: an unmet medical need. Oncologist 16:Suppl. 1 (2011), S1–S11.
31. [31] Palma, G., Frasci, G., Chirico, A., Esposito, E., Siani, C., Saturnino, C., Arra, C., Ciliberto, G., Giordano, A., D'Aiuto, M., Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget 6 (2015), 26560–26574.
32. [32] Mustacchi, G., De Laurentiis, M., The role of taxanes in triple-negative breast cancer: literature review. Drug Des. Dev. Ther. 9 (2015), 4303–4318.
33. [33] Pannu, V., Karna, P., Sajja, H.K., Shukla, D., Aneja, R., Synergistic antimicrotubule therapy for prostate cancer. Biochem. Pharmacol. 81 (2011), 478–487.
34. [34] Barken, I., Geller, J., Rogosnitzky, M., Noscapine inhibits human prostate cancer progression and metastasis in a mouse model. Anticancer Res. 28 (2008), 3701–3704.
35. [35] Madan, J., Baruah, B., Nagaraju, M., Abdalla, M.O., Yates, C., Turner, T., Rangari, V., Hamelberg, D., Aneja, R., Molecular cycloencapsulation augments solubility and improves therapeutic index of brominated noscapine in prostate cancer cells. Mol. Pharm. 9 (2012), 1470–1480.
36. [36] Wagner, E.F., Nebreda, A.R., Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 9 (2009), 537–549.
37. [37] Shi, Z., Liang, Y.J., Chen, Z.S., Wang, X.W., Wang, X.H., Ding, Y., Chen, L.M., Yang, X.P., Fu, L.W., Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol. Ther. 5 (2006), 39–47.
38. [38] Aneja, R., Vangapandu, S.N., Lopus, M., Chandra, R., Panda, D., Joshi, H.C., Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma. Mol. Pharmacol. 69 (2006), 1801–1809.
39. [39] Debono, A.J., Mistry, S.J., Xie, J., Muthiah, D., Phillips, J., Ventura, S., Callaghan, R., Pouton, C.W., Capuano, B., Scammells, P.J., The synthesis and biological evaluation of multifunctionalised derivatives of noscapine as cytotoxic agents. ChemMedChem 9 (2014), 399–410.
40. [40] Landen, J.W., Lang, R., McMahon, S.J., Rusan, N.M., Yvon, A.M., Adams, A.W., Sorcinelli, M.D., Campbell, R., Bonaccorsi, P., Ansel, J.C., Archer, D.R., Wadsworth, P., Armstrong, C.A., Joshi, H.C., Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res. 62 (2002), 4109–4114.
41. [41] Khawar, I.A., Kim, J.H., Kuh, H.J., Improving drug delivery to solid tumors: priming the tumor microenvironment. J. Control Release 201 (2015), 78–89.
42. [42] Holback, H., Yeo, Y., Intratumoral drug delivery with nanoparticulate carriers. Pharm. Res. 28 (2011), 1819–1830.
43. [43] Durymanov, M.O., Rosenkranz, A.A., Sobolev, A.S., Current approaches for improving intratumoral accumulation and distribution of nanomedicines. Theranostics 5 (2015), 1007–1020.
44. [44] Li, Y., Wang, J., Wientjes, M.G., Au, J.L., Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv. Drug. Deliv. Rev. 64 (2012), 29–39.
45. [45] Patel, K., Patil, A., Mehta, M., Gota, V., Vavia, P., Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: preparation, characterization and antitumor activity. Int. J. Pharm. 472 (2014), 214–223.